Back to top

cell-therapy: Archive

Zacks Equity Research

Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates

Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.

NVSNegative Net Change INCYNegative Net Change MESONegative Net Change ALXONegative Net Change

Zacks Equity Research

Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study

Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.

JNJNegative Net Change ABBVNegative Net Change BGNENegative Net Change MBIOPositive Net Change